Global anti-suicide drugs market was valued at US$ 3,318.3 million in 2015 and is expected to witness a moderate CAGR of 4.2%

Suicidal thoughts can be aroused due to various underlying factors such as financial burden, social issues or drug side effects. Treatment for suicidal thoughts includes psychotherapy, medications, addiction treatment, and family support. Anti-depressants and anti-psychotics are the most widely used medications for treating suicidal tendencies. According to the World Health Organization (WHO), over 800,000 people die due to suicide annually. Development of an effective anti-suicidal drug could be a major breakthrough in reducing the death toll. Currently, non-profit organizations such as Stop Suicide, Stop Youth Suicide, and American Foundation for Suicide Prevention are providing moral and social support to people with reported suicidal thoughts. This however, is ineffective until the organization is alerted of the person at risk for suicide.

Market Dynamics

Off-label use of these drugs for suicidal ideation has been a practice for years, as there are no approved anti-suicide specific drug yet. However, the dynamics is expected to change in the following few years with the launch of first oral therapeutic drug for acute suicidal ideation. This would disrupt the use of antidepressants and anti-psychotic drugs for the treatment of suicidal tendencies. Suicidal incidences are high in low and middle income countries according to the WHO 2016 statistics. Although the incidence in Asia, East Africa, and Eastern European region is high, these regions lag in terms of availability of affordable medications and healthcare facilities. Therefore developed economies of North America and Western Europe are key target regions for manufacturers in the near future. Rampant economic growth and projected strengthening of the healthcare infrastructure in emerging economies in towards the first half of the following decade is projected to shift the focus of these companies towards highly populous regions of India and China in the long run.

Fill the form for an exclusive sample of this report @ https://www.coherentmarketinsights.com/insight/request-sample/10

Market Taxonomy

This report segments the global anti-suicide drugs market on the basis of chemistry type, and geography. On the basis of chemistry type, the market is categorized into anti-depressants and anti-anxiety drugs, anti-psychotic drugs, NMDA antagonist and antibiotic analogs. For comprehensive understanding of market dynamics, the global anti-suicide devices market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key features of the study:

This report provides in-depth analysis of the anti-suicide drugs and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global anti-suicide drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans

Key companies covered as a part of this study include Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, Allergan plc, GlaxoSmithKline plc, Merck & Co., Inc., Lundbeck A/S, NeuroRx, Inc., and Johnson & Johnson

Insights from this report would allow marketers and the management of companies to make informed decision with respect to their future product launch, competitive scenario, geographic expansion, and marketing tactics

The global anti-suicide devices market report caters to various stakeholders in this industry, including investors, drug manufacturers, distributors and suppliers, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the anti-suicide drugs market would provide stakeholders vital inputs to make strategic decisions accordingly

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/10

Anti-Suicide Drugs Market to be on High Growth Trajectory Post Launch of Anti-Suicidal Drug

NeuroRx Pharma has developed a novel anti-suicidal product Cyclurad (D-cycloserine and Lurasidone) which is indicated for Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. The estimated commercialization of the drug post-2020 is expected to be a major breakthrough innovation for the anti-suicide drugs market. Moreover, introduction of other such novel drugs for suicide would augment the anti-suicide market growth. People with major depressive disorder and risk for suicide would greatly benefit from such novel drug therapies.

High Suicidal Rates to Contribute Towards the Positive Anti-Suicide Drugs Market Outlook

According to the World Health Organization (WHO), suicide accounted for 1.4% of the total deaths worldwide in 2012, accounting for around 800 thousand deaths each year. Russia, India, Republic of Korea, Guyana, Lithuania, Sri Lanka, Hungary, Kazakhstan, and Japan are among the nations with high suicidal rates as per the WHO 2012 data. Emerging nations therefore possess immense opportunity for anti-suicidal drugs. However, being the first ever oral anti-suicidal therapeutic drug, companies are likely to capture the anti-suicide drugs market in developed regions such as North America and Western Europe. This mainly due to rapid adoption of new therapies and accessibility to healthcare facilities in these regions as compared to emerging economies.

Browse Global Strategic Business Report: https://www.coherentmarketinsights.com/market-insight/anti-suicide-drugs-market-10

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.